Intellia Therapeutics (NTLA) Tops Q3 EPS by 12c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Intellia Therapeutics (NTLA) Tops Q3 EPS by 12c, Revenues Beat

Intellia Therapeutics Announces Third Quarter 2020 Financial Results

November 5, 2020 7:30 AM EST

On track to dose first patient by year-end with NTLA-2001 for the treatment of transthyretin amyloidosis (ATTR), following regulatory authorization to initiate Phase 1 clinical trial Anticipates submitting an IND or IND-equivalent for lead TCR-T cell therapy, NTLA-5001 for the treatment of acute myeloid leukemia (AML), in 1H 2021Expects to submit an IND or IND-equivalent... More